Hexagon Capital Partners’s Ascendis Pharma A/S ASND Stock Holding History

Hexagon Capital Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15	Closed	-$2.34K	–	203
2025 Q1	$2.34K	Buy	15 +2	+15%	+$286	﹤0.01%	1359
2024 Q4	$1.79K	Buy	+13	New	+$1.71K	﹤0.01%	1450
2023 Q2	–	Sell	-53	Closed	-$5.68K	–	1430
2023 Q1	$5.68K	Sell	53 -6	-10%	-$686	﹤0.01%	867
2022 Q4	$7.21K	Hold	59	–	–	﹤0.01%	816
2022 Q3	$6K	Buy	+59	New	+$5.59K	﹤0.01%	881

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Hexagon Capital Partners's ASND Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Ascendis Pharma A/S (ASND) in Q2 2025, closing a stake of 15 shares — an estimated $2.34K sold.

Hexagon Capital Partners first reported a position in ASND in Q3 2022 and held it in 5 quarters. The position peaked at $7.21K in Q4 2022. 247 funds tracked by Wall St. Rank hold ASND as of Q2 2025.

Hexagon Capital Partners reported no remaining Ascendis Pharma A/S position as of Q2 2025 after selling out during the quarter.
Hexagon Capital Partners sold 15 Ascendis Pharma A/S shares in Q2 2025, an estimated $2.34K.
Hexagon Capital Partners first reported a position in Ascendis Pharma A/S in Q3 2022 and held it in 5 quarters.
Hexagon Capital Partners's Ascendis Pharma A/S position peaked at $7.21K in Q4 2022.
247 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.